CBIO — CRESCENT BIOPHARMA, INC.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on CBIO
| date | signal | measured base rate |
|---|---|---|
| 2026-07-15 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-04-15 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-16 | Kiselak Tomas Director | Open-market purchase | 853.5K | 14.50 | 12.4M |
| 2026-07-16 | Fairmount Funds Management LLC Director | Open-market purchase | 853.5K | 14.50 | 12.4M |
| 2026-07-16 | Fairmount Healthcare Fund II L.P. Director | Open-market purchase | 853.5K | 14.50 | 12.4M |
| 2026-07-16 | Harwin Peter Evan Director | Open-market purchase | 853.5K | 14.50 | 12.4M |
| 2026-06-22 | Brumm Joshua T Chief Executive Officer | Open-market sale 10b5-1 plan | 42.3K | 17.99 | 761.1K |
| 2026-06-22 | McNeill Jonathan President and COO | Open-market sale 10b5-1 plan | 20.5K | 17.99 | 369.7K |
| 2026-06-22 | Pinkas Jan Chief Scientific Officer | Open-market sale 10b5-1 plan | 1.3K | 17.99 | 23.2K |
| 2026-06-22 | Im Ellie Eunkyung Chief Medical Officer | Open-market sale 10b5-1 plan | 1.2K | 17.99 | 21.9K |
| 2026-06-22 | Bispham Barbara Harlin See Remarks | Open-market sale 10b5-1 plan | 1.2K | 17.99 | 21.9K |
| 2026-06-22 | Scalzo Richard William Chief Financial Officer | Open-market sale 10b5-1 plan | 1.1K | 17.99 | 20.0K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| FMR LLC | 75.9M | 4.1M |
| BVF INC/IL | 50.5M | 2.7M |
| Fairmount Funds Management LLC | 50.5M | 2.7M |
| Venrock Adviser, LLC | 39.2M | 2.1M |
| FCPM III SERVICES B.V. | 30.8M | 1.7M |
| Balyasny Asset Management L.P. | 27.7M | 1.5M |
| Vestal Point Capital, LP | 27.6M | 1.5M |
| Opaleye Management Inc. | 24.1M | 1.3M |
| TANG CAPITAL MANAGEMENT LLC | 21.3M | 1.2M |
| VANGUARD CAPITAL MANAGEMENT LLC | 14.7M | 801.4K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about CBIO
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →